The role of FDG-PET in the management of non-small cell lung carcinoma

Annals of the Academy of Medicine Singapore

Volumn 33, Issue 2, 2004, Pages 166-174

  Shon, I A Ho ^a   Maisey, M N ^b  

^a LIVERPOOL HOSPITAL   (Australia)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

18F fluorodeoxyglucose; Non small cell lung carcinoma; Positron emission tomography; Solitary pulmonary nodule

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ALGORITHM; CANCER SCREENING; CANCER STAGING; CLINICAL RESEARCH; COST BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; LUNG NODULE; LUNG NON SMALL CELL CANCER; MEDLINE; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT PLANNING;

EID: 2542484384     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Ries L, Eisner M, Kosary C, Hankey B, Miller B, Clegg L, et al. SEER Cancer Statistics Review, 1975-2000, National Cancer Institute, 2003. Available at http://seer.cancer.gov/csr/1975_2000. Accessed 22 July 2003.
2. Mortality: Cancer Research UK 2003. Mortality UK, CancerStats, 2003. Available at http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/. Accessed 22 July 2003.
3. Warburg O. The Metabolism of Tumors. London: Constable, 1930: 129-69.
4. Isselbacher KJ. Increased uptake of amino acids and 2-deoxy-D-glucose by virus-transformed cells in culture. Proc Natl Acad Sci USA 1972;69:585-9.
5. Bello LJ. Regulation of thymidine kinase synthesis in human cells. Exp Cell Res 1974;89:263-74.
6. Mueckler M. Facilitative glucose transporters. Eur J Biochem 1994;219:713-25.
7. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978;19:1154-61.
8. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999;40:556-65.
9. Smith TA. FDG uptake, tumour characteristics and response to therapy: a review. Nucl Med Commun 1998;19:97-105.
10. Buck AK, Schirrmeister H, Hetzel M, Von Der Heide M, Halter G, Glatting G, et al. 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002;62:3331-4.
11. Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, et al. In vivo assessment of tumor hypoxia in lung cancer with (60)Cu-ATSM. Eur J Nucl Med Mol Imaging 2003;30:844-50.
12. Midthun DE, Swensen SJ, Jett JR. Approach to the solitary pulmonary nodule. Mayo Clin Proc 1993;68:378-85.
13. Shulkin AN. Management of the indeterminate solitary pulmonary nodule: a pulmonologist's view. Ann Thorac Surg 1993;56:743-4.
14. Swensen SJ, Viggiano RW, Midthun DE, Muller NL, Sherrick A, Yamashita K, et al. Lung nodule enhancement at CT: multicenter study. Radiology 2000;214:73-80.
15. Viggiano RW, Swensen SJ, Rosenow EC, III. Evaluation and management of solitary and multiple pulmonary nodules. Clin Chest Med 1992;13:83-95.
16. Ho Shon I, O'Doherty MJ, Maisey MN. Positron emission tomography in lung cancer. Semin Nucl Med 2002;32:240-71.
17. Kubota K, Matsuzawa T, Fujiwara T, Ito M, Hatazawa J, Ishiwata K, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990;31:1927-32.
18. Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr 1979;3:299-308.
19. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998;16:1075-84.
20. Rege SD, Hoh CK, Glaspy JA, Aberle DR, Dahlbom M, Razavi MK, et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993;72:82-90.
21. Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick MP. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest 1993;104:997-1002.
22. Yap CS, Schiepers C, Fishbein MC, Phelps ME, Czernin J. FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma? Eur J Nucl Med Mol Imaging 2002;29:1166-73.
23. Marom EM, Sarvis S, Herndon JE, II, Patz EF, Jr. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology 2002;223:453-9.
24. Dewan NA, Reeb SD, Gupta NC, Gobar LS, Scott WJ. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest 1995;108:441-6.
25. Knight SB, Delbeke D, Stewart JR, Sandler MP. Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest 1996;109:982-8.
26. Lowe VJ, Duhaylongsod FG, Patz EF, Delong DM, Hoffman JM, Wolfe WG, et al. Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology 1997;202:435-9.
27. Wilkinson MD, Fulham MJ, McCaughan BC, Constable CJ. Invasive aspergillosis mimicking stage IIIA non-small cell lung cancer on FDG positron emission tomography. Clin Nucl Med 2003;28: 234-5.
28. Hubner KF, Buonocore E, Singh SK, Gould HR, Cotten DW. Characterization of chest masses by FDG positron emission tomography. Clin Nucl Med 1995;20:293-8.
29. Hubner KF, Buonocore E, Gould HR, Thie J, Smith GT, Stephens S, et al. Differentiating benign from malignant lung lesions using " quantitative" parameters of FDG PET images. Clin Nucl Med 1996;21:941-9.
30. Prauer HW, Weber WA, Romer W, Treumann T, Ziegler SI, Schwaiger M. Controlled prospective study of positron emission tomography using the glucose analogue [18F]fluorodeoxyglucose in the evaluation of pulmonary nodules. Br J Surg 1998;85:1506-11.
31. Calhoun P, Feldman PS, Armstrong P, Black WC, Pope TL, Minor GR, et al. The clinical outcome of needle aspirations of the lung when cancer is not diagnosed. Ann Thorac Surg 1986;41:592-6.
32. Schreiber G, McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest 2003;123:S115-S128.
33. Gambhir SS, Shepherd JE, Shah BD, Hart E, Hoh CK, Valk PE, et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998;16:2113-25.
34. Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW, et al. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. Eur J Nucl Med 2000;27:1441-56.
35. Seely JM, Mayo JR, Miller RR, Muller NL. T1 lung cancer: prevalence of mediastinal nodal metastases and diagnostic accuracy of CT. Radiology 1993;186:129-32.
36. Gould MK, Sanders GD, Barnett PG, Rydzak CE, Maclean CC, McClellan MB, et al. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Ann Intern Med 2003;138:724-35.
37. Hain SF, Curran KM, Beggs AD, Fogelman I, O'Doherty MJ, Maisey MN. FDG-PET as a "metabolic biopsy" tool in thoracic lesions with indeterminate biopsy. Eur J Nucl Med 2001;28:1336-40.
38. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718-23.
39. Feld R, Abratt R, Graziano S, Jassem J, Lacquet L, Ninane V, et al. Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Lung Cancer 1997;17:S3-10.
40. Ginsberg R, Evertt E, Rosenzweig K. Non-small cell lung cancer. In: DeVita V, Hellman S, Rosenberg S, editors. Cancer Principles and Practice of Oncology. Vol. 1. Philadelphia: Lippincott Williams and Wilkins, 2001:925-83.
41. Glazer GM, Gross BH, Quint LE, Francis IR, Bookstein FL, Orringer MB. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. AJR Am J Roentgenol 1985;144:261-5.
42. Dales RE, Stark RM, Raman S. Computed tomography to stage lung cancer. Approaching a controversy using meta-analysis. Am Rev Respir Dis 1990;141:1096-101.
43. Prenzel KL, Monig SP, Sinning JM, Baldus SE, Brochhagen HG, Schneider PM, et al. Lymph node size and metastatic infiltration in non-small cell lung cancer. Chest 2003;123:463-7.
44. British Thoracic Society and Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party. BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. Thorax 2001;56: 89-108.
45. Oliver TW, Jr, Bernardino ME, Miller JI, Mansour K, Greene D, Davis WA. Isolated adrenal masses in non-small cell bronchogenic carcinoma. Radiology 1984;153:217-8.
46. Luke WP, Pearson FG, Todd TR, Patterson GA, Cooper JD. Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung. J Thorac Cardiovasc Surg 1986;91:53-6.
47. De Leyn P, Vansteenkiste J, Cuypers P, Deneffe G, Van Raemdonck D, Coosemans W, et al. Role of cervical mediastinoscopy in staging of non-small cell lung cancer without enlarged mediastinal lymph nodes on CT scan. Eur J Cardiothorac Surg 1997;12:706-12.
48. Fischer B, Mortensen J, Hojgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic quantitiative review. Lancet Oncol 2001;2:659-66.
49. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 1999;213:530-6.
50. Reske SN, Kotzerke J. FDG-PET for clinical use Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 2001;28:1707-23.
51. Roberts PF, Follette DM, von Haag D, Park JA, Valk PE, Pounds TR, et al. Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thorac Surg 2000; 70:1154-60.
52. Guhlmann A, Storck M, Kotzerke J, Moog F, Sunder-Plassmann L, Reske SN. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET). Thorax 1997;52:438-41.
53. Gupta NC, Tamim WJ, Graeber GG, Bishop HA, Hobbs GR. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest 2001;120: 521-7.
54. Albes JM, Lietzenmayer R, Schott U, Schulen E, Wehrmann M, Ziemer G. Improvement of non-small cell lung cancer staging by means of positron emission tomography. Thorac Cardiovasc Surg 1999;47:42-7.
55. Brudin LH, Valind SO, Rhodes CG, Pantin CF, Sweatman M, Jones T, et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 1994;21:297-305.
56. Silvestri GA, Tanoue LT, Margolis ML, Barker J, Detterbeck F. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest 2003;123:S147-56.
57. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994;191:371-7.
58. Valk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Greiss HB, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995;60:1573-82.
59. Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, et al. Preoperative staging of non-small cell lung cancer with positron emission tomography. N Engl J Med 2000;343:254-61.
60. Poncelet AJ, Lonneux M, Coche E, Weynand B, Noirhomme P. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma. Eur J Cardiothorac Surg 2001;20: 468-75.
61. Scott WJ, Schwabe JL, Gupta NC, Dewan NA, Reeb SD, Sugimoto JT. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F] fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group. Ann Thorac Surg 1994;58:698-703.
62. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A, et al. Lymph node staging in non-small cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998;16:2142-9.
63. Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 2000;27: 1598-609.
64. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003;123: S137-S146.
65. Marom EM, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999;212:803-9.
66. Bury T, Dowlati A, Paulus P, Corhay JL, Hustinx R, Ghaye B, et al. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J 1997;10:2529-34.
67. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224:748-56.
68. Boland GW, Goldberg MA, Lee MJ, Mayo-Smith WW, Dixon J, McNicholas MM, et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;194:131-4.
69. Griffeth LK, Rich KM, Dehdashti F, Simpson JR, Fusselman MJ, McGuire AH, et al. Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology 1993;186:37-44.
70. Saunders CA, Dussek JE, O'Doherty MJ, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999;67:790-7.
71. Lewis P, Griffin S, Marsden P, Gee T, Nunan T, Malsey M, et al. Wholebody 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994;344:1265-6.
72. Weng E, Tran L, Rege S, Safa A, Sadeghi A, Juillard G, et al. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer. Am J Clin Oncol 2000;23:47-52.
73. van Tinteren H, Hoekstra O, Smit E, van den Bergh J, Schreurs A, Stallaert R, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359: 1388-92.
74. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small cell lung carcinoma. J Nucl Med 1996;37:1428-36.
75. Scott WJ, Shepherd J, Gambhir SS. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg 1998;66:1876-85.
76. Verboom P, Van Tinteren H, Hoekstra OS, Smit EF, Van Den Bergh JH, Schreurs AJ, et al. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging 2003;30:144-9.
77. Vokes EE, Herndon JE, II, Crawford J, Leopold KA, Perry MC, Miller AA, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002;20:4191-8.
78. MacManus MP, Hicks RJ, Matthews JP, Hogg A, McKenzie AF, Wirth A, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:287-93.
79. Hoekstra CJ, Stroobants SG, Hoekstra OS, Vansteenkiste J, Biesma B, Schramel FJ, et al. The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer 2003;39:151-7.
80. MacManus MP, Hicks RJ, Ball DL, Kalff V, Matthews JP, Salminen E, et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with non-small cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 2001;92:886-95.
81. MacManus MP, Wong K, Hicks RJ, Matthews JP, Wirth A, Ball DL. Early mortality after radical radiotherapy for non-small cell lung cancer: comparison of PET-staged and conventionally-staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys 2002;52: 351-61.
82. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, De Leyn PR, De Wever W, Verbeken EK, et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 2000;55:317-24.
83. Erdi YE, Rosenzweig K, Erdi AK, Macapinlac HA, Hu YC, Braban LE, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002;62:51-60.
84. Kiffer JD, Berlangieri SU, Scott AM, Quong G, Feigen M, Schumer W, et al. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 1998;19:167-77.
85. Featherstone C, Holloway L, Vinod S, Ho Shon I, Kaplan A. The Influence of 18FDG-PET on conformal radiotherapy planning for patients with non-small cell lung carcinoma (NSCLC), International Congress of Radiation Research, Brisbane, 2003.
86. Nestle U, Walter K, Schmidt S, Licht N, Nieder C, Motaref B, et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 1999;44:593-7.
87. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verbeken EK. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol 1998;9:1193-8.
88. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002;35:179-87.
89. Cerfolio RJ, Ojha B, Mukherjee S, Pask AH, Bass CS, Katholi CR. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg 2003;125:938-44.
90. MacManus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small cell lung cancer. J Clin Oncol 2003;21:1285-92.
91. Frank A, Lefkowitz D, Jaeger S, Gobar L, Sunderland J, Gupta N, et al. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 1995;32:1495-512.
92. O'Doherty MJ. PET in oncology I - lung, breast, soft tissue sarcoma. Nucl Med Commun 2000;21:224-9.
93. Inoue T, Kim EE, Komaki R, Wong FC, Bassa P, Wong WH, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995;36:788-93.
94. Patz EF Jr, Lowe VJ, Hoffman JM, Paine SS, Harris LK, Goodman PC. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 1994;191:379-82.
95. Dhital K, Saunders CA, Seed PT, O'Doherty MJ, Dussek J. [(18)F] fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 2000;18:425-8.
96. Ahuja V, Coleman RE, Herndon J, Patz EF, Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma. Cancer 1998;83:918-24.
97. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999;17:3201-6.
98. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small cell lung cancer with integrated positron emission tomography and computed tomography. N Engl J Med 2003;348: 2500-7.
99. Cohade C, Osman M, Marshall LN, Wahl RN. PET-CT: accuracy of PET and CT spatial registration of lung lesions. Eur J Nucl Med Mol Imaging 2003;30:721-6.
100. Skalski J, Wahl RL, Meyer CR. Comparison of mutual information-based warping accuracy for fusing body CT and PET by 2 methods: CT mapped onto PET emission scan versus CT mapped onto PET transmission scan. J Nucl Med 2002;43:1184-7.